PDF(Pubmed)
Abstract：
BACKGROUND: Data on the epidemiology of inflammatory bowel disease (IBD) in the Middle East are scarce. We aimed to describe the clinical phenotype, disease course, and medication usage of IBD cases from Iran in the Middle East.
METHODS: We conducted a cross-sectional study of registered IBD patients in the Iranian Registry of Crohn\'s and Colitis (IRCC) from 2017 until 2022. We collected information on demographic characteristics, past medical history, family history, disease extent and location, extra-intestinal manifestations, IBD medications, and activity using the IBD-control-8 questionnaire and the Manitoba IBD index, admissions history, history of colon cancer, and IBD-related surgeries.
RESULTS: In total, 9746 patients with ulcerative colitis (UC) (n=7793), and Crohn\'s disease (CD) (n=1953) were reported. The UC to CD ratio was 3.99. The median age at diagnosis was 29.2 (IQR: 22.6,37.6) and 27.6 (IQR: 20.6,37.6) for patients with UC and CD, respectively. The male-to-female ratio was 1.28 in CD patients. A positive family history was observed in 17.9% of UC patients. The majority of UC patients had pancolitis (47%). Ileocolonic involvement was the most common type of involvement in CD patients (43.7%), and the prevalence of stricturing behavior was 4.6%. A prevalence of 0.3% was observed for colorectal cancer among patients with UC. Moreover,15.2% of UC patients and 38.4% of CD patients had been treated with anti-tumor necrosis factor (anti-TNF).
CONCLUSIONS: In this national registry-based study, there are significant differences in some clinical phenotypes such as the prevalence of extra-intestinal manifestations and treatment strategies such as biological use in different geographical locations.
METHODS: We conducted a cross-sectional study of registered IBD patients in the Iranian Registry of Crohn\'s and Colitis (IRCC) from 2017 until 2022. We collected information on demographic characteristics, past medical history, family history, disease extent and location, extra-intestinal manifestations, IBD medications, and activity using the IBD-control-8 questionnaire and the Manitoba IBD index, admissions history, history of colon cancer, and IBD-related surgeries.
RESULTS: In total, 9746 patients with ulcerative colitis (UC) (n=7793), and Crohn\'s disease (CD) (n=1953) were reported. The UC to CD ratio was 3.99. The median age at diagnosis was 29.2 (IQR: 22.6,37.6) and 27.6 (IQR: 20.6,37.6) for patients with UC and CD, respectively. The male-to-female ratio was 1.28 in CD patients. A positive family history was observed in 17.9% of UC patients. The majority of UC patients had pancolitis (47%). Ileocolonic involvement was the most common type of involvement in CD patients (43.7%), and the prevalence of stricturing behavior was 4.6%. A prevalence of 0.3% was observed for colorectal cancer among patients with UC. Moreover,15.2% of UC patients and 38.4% of CD patients had been treated with anti-tumor necrosis factor (anti-TNF).
CONCLUSIONS: In this national registry-based study, there are significant differences in some clinical phenotypes such as the prevalence of extra-intestinal manifestations and treatment strategies such as biological use in different geographical locations.
摘要：
背景：中东炎症性肠病（IBD）的流行病学数据很少。我们的目的是描述临床表型，病程,以及中东伊朗IBD病例的药物使用情况。
方法：我们对2017年至2022年伊朗克罗恩病和结肠炎（IRCC）注册的IBD患者进行了横断面研究。我们收集了有关人口统计特征的信息，既往病史,家族史,疾病范围和位置，肠外表现,IBD药物,和活动使用IBD控制-8问卷和马尼托巴IBD指数，招生历史，结肠癌病史,和IBD相关的手术。
结果：总计，9746例溃疡性结肠炎（UC）患者（n=7793），报告了克罗恩病（CD）（n=1953）。UC与CD的比率为3.99。UC和CD患者的诊断年龄中位数为29.2岁（IQR：22.6,37.6）和27.6岁（IQR：20.6,37.6），分别。CD患者的男女比例为1.28。在17.9%的UC患者中观察到阳性家族史。大多数UC患者患有泛结肠炎(47%)。合并结肠受累是CD患者最常见的受累类型（43.7％），狭窄行为的患病率为4.6%。在UC患者中，结直肠癌的患病率为0.3％。此外，15.2％的UC患者和38.4％的CD患者接受了抗肿瘤坏死因子（anti-TNF）治疗。
结论：在这项基于国家注册的研究中，一些临床表型存在显著差异,如肠道外表现的患病率和治疗策略,如不同地理位置的生物使用.
方法：我们对2017年至2022年伊朗克罗恩病和结肠炎（IRCC）注册的IBD患者进行了横断面研究。我们收集了有关人口统计特征的信息，既往病史,家族史,疾病范围和位置，肠外表现,IBD药物,和活动使用IBD控制-8问卷和马尼托巴IBD指数，招生历史，结肠癌病史,和IBD相关的手术。
结果：总计，9746例溃疡性结肠炎（UC）患者（n=7793），报告了克罗恩病（CD）（n=1953）。UC与CD的比率为3.99。UC和CD患者的诊断年龄中位数为29.2岁（IQR：22.6,37.6）和27.6岁（IQR：20.6,37.6），分别。CD患者的男女比例为1.28。在17.9%的UC患者中观察到阳性家族史。大多数UC患者患有泛结肠炎(47%)。合并结肠受累是CD患者最常见的受累类型（43.7％），狭窄行为的患病率为4.6%。在UC患者中，结直肠癌的患病率为0.3％。此外，15.2％的UC患者和38.4％的CD患者接受了抗肿瘤坏死因子（anti-TNF）治疗。
结论：在这项基于国家注册的研究中，一些临床表型存在显著差异,如肠道外表现的患病率和治疗策略,如不同地理位置的生物使用.
